Quinolone derivatives as antitubercular drugs

被引：27

作者：

Asif, Mohammad ^{[1
]}

Siddiqui, Anees A. ^{[2
]}

Husain, Asif ^{[2
]}

机构：

[1] Guru Ram PG Inst Management & Technol, Dept Pharm, Dehra Dun 248009, Uttarakhand, India

[2] Jamia Hamdard, Fac Pharm, New Delhi, India

来源：

MEDICINAL CHEMISTRY RESEARCH | 2013年 / 22卷 / 03期

关键词：

Tuberculosis; Chemotherapeutic agents; Multidrug-resistant; Quinolones; IN-VITRO ACTIVITY; RESISTANT STREPTOCOCCUS-PNEUMONIAE; STATIONARY-PHASE CULTURES; MYCOBACTERIUM-TUBERCULOSIS; DNA GYRASE; FLUOROQUINOLONE RESISTANCE; PULMONARY TUBERCULOSIS; BACTERICIDAL ACTIVITY; MURINE TUBERCULOSIS; LOGARITHMIC-PHASE;

D O I：

10.1007/s00044-012-0101-3

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

New chemotherapeutic drugs are the need to improve tuberculosis (TB) control particularly due to the emergence of multidrug-resistant strains and extensively drug-resistant strains of TB. These antitubercular compounds have different chemical moieties in their structure. Quinolones are generally used against many Gram-positive and Gram-negative bacteria. They are also active against atypical mycobacteria. Some quinolones (ciprofloxacin, levofloxacin, etc.) inhibit strains of Mycobacterium tuberculosis at concentrations < 2.0 mu g/mL. Fluoroquinolones are an important recent addition to the drugs available for TB, especially for strains that are resistant to first-line agents. The present review provides an overview of the drugs that are being used have quinolone moieties in TB treatment.

引用

页码：1029 / 1042

页数：14

共 88 条

[1] The clinical use of fluoroquinolones for the treatment of mycobacterial diseases [J].

Alangaden, GJ ;

Lerner, SA .

CLINICAL INFECTIOUS DISEASES, 1997, 25 (05) :1213-1221

[2] CHARACTERIZATION OF FLUOROQUINOLONE-RESISTANT MUTANT STRAINS OF MYCOBACTERIUM-TUBERCULOSIS SELECTED IN THE LABORATORY AND ISOLATED FROM PATIENTS [J].

ALANGADEN, GJ ;

MANAVATHU, EK ;

VAKULENKO, SB ;

ZVONOK, NM ;

LERNER, SA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (08) :1700-1703

[3] In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis [J].

Alvirez-Freites, EJ ;

Carter, JL ;

Cynamon, MH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) :1022-1025

[4] Mycobacterium tuberculosis DNA gyrase:: Interaction with quinolones and correlation with antimycobacterial drug activity [J].

Aubry, A ;

Pan, XS ;

Fisher, LM ;

Jarlier, V ;

Cambau, E .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) :1281-1288

[5] Quantitative structure-activity relationship (QSAR) studies of quinolone antibacterials against M-fortuitum and M-smegmatis using theoretical molecular descriptors [J].

Bagchi, Manish C. ;

Mills, Denise ;

Basak, Subhash C. .

JOURNAL OF MOLECULAR MODELING, 2007, 13 (01) :111-120

[6]

Balfour JAB, 2000, DRUGS, V59, P115

[7] Foreword from the co-editor-in-chief [J].

Brennan, PJ .

TUBERCULOSIS, 2001, 81 (1-2) :1-1

[8] The safety profile of the fluoroquinolones [J].

Bertino, J ;

Fish, D .

CLINICAL THERAPEUTICS, 2000, 22 (07) :798-817

[9] ANTIMICROBIAL ACTIVITY OF CS-940, A NEW TRIFLUORINATED QUINOLONE [J].

BIEDENBACH, DJ ;

SUTTON, LD ;

JONES, RN .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (10) :2325-2330

[10] Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada [J].

Bozeman, L ;

Burman, W ;

Metchock, B ;

Welch, L ;

Weiner, M .

CLINICAL INFECTIOUS DISEASES, 2005, 40 (03) :386-391

← 1 2 3 4 5 6 7 8 9 →